US-CONGRESS HR1266: Combating Illicit Xylazine Act
The House Judiciary Committee advanced HR1266, the Combating Illicit Xylazine Act, with a unanimous 48-0 vote. The bill aims to address the illicit use of xylazine by adding it to the Controlled Substances Act as a Schedule III drug, which would impose new DEA regulations on legitimate handlers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Pharmaceutical manufacturers, API suppliers, and compounding outsourcing facilities that handle xylazine or products containing it. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified; the bill is still in the legislative process.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The bill, if enacted, would place xylazine under Schedule III of the Controlled Substances Act, requiring DEA registration, quotas, and security controls for all legitimate handlers.
Who it affects
Pharmaceutical manufacturers, API suppliers, and compounding outsourcing facilities that handle xylazine or products containing it.
What you must do
Monitor the bill's progress and prepare for potential DEA registration and compliance requirements if it becomes law.
Deadline
Not specified; the bill is still in the legislative process.
Source: https://www.congress.gov/bill/119th-congress/house-bill/1266
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs; Revised Draft Guidance for Industry; Availability
- Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availability
- Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
- PRESCRIPTION DRUGS—M.D. Tenn.: Court rejects AbbVie’s challenge to Tennessee contract pharmacy law - vitallaw.com
- WY HB0013: Ivermectin-no prescription required.